首页 › 乳腺癌 › 加利福尼亚州 › Mountain View
Mountain View CA 乳腺癌临床试验
26项针对 乳腺癌的研究正在 Mountain View及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
招募中3 期
- Stanford Women's Cancer Center, Palo Alto · 距离 5 英里
A Study of PHST001 in Advanced Solid Tumors
招募中1 期
- Stanford University School of Medicine, Palo Alto · 距离 5 英里
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
招募中3 期
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
招募中1/2 期
- Stanford Medicine Cancer Center, Stanford · 距离 5 英里
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
招募中1 期
- Stanford University Medical Center, Stanford · 距离 5 英里
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
招募中1 期
- Stanford University Medical Center, Stanford · 距离 5 英里
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- Stanford Cancer Center, Palo Alto · 距离 5 英里
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
招募中3 期
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · 距离 5 英里
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Stanford Women's Cancer Center, Palo Alto · 距离 5 英里
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
招募中1 期
- Stanford University Hospital, Stanford · 距离 5 英里
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
招募中3 期
- Research Site, Palo Alto · 距离 5 英里
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
招募中2 期
- Stanford Cancer Institute, Palo Alto · 距离 5 英里
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
招募中3 期
- Palo Alto Medical Foundation Research Center, Palo Alto · 距离 5 英里
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 距离 5 英里
- 以及另外 1 项
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
招募中2 期
- Stanford University, Stanford · 距离 5 英里
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Local Institution - 0358, Stanford · 距离 5 英里
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · 距离 5 英里
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
招募中1 期
- Stanford University Medical Center, Palo Alto · 距离 5 英里
Magnetic Resonance Imaging of Breast Cancer
招募中欢迎健康志愿者
- Stanford University School of Medicine, Stanford · 距离 5 英里
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
招募中观察性研究
- Stanford University School of Medicine, Stanford · 距离 5 英里
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 距离 5 英里
- Stanford Cancer Institute Palo Alto, Palo Alto · 距离 5 英里
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
招募中1 期
- Stanford Cancer Institute, Stanford · 距离 5 英里
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
招募中
- Stanford University, Stanford · 距离 5 英里
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
招募中观察性研究
- Stanford Cancer Institute, Palo Alto · 距离 5 英里
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Stanford · 距离 5 英里
其他城市的 乳腺癌试验
- New York City, NY136 项研究
- Houston, TX126 项研究
- Boston, MA112 项研究
- Nashville, TN81 项研究
- Los Angeles, CA73 项研究
- Edison, NJ68 项研究
- St. Louis, MO64 项研究
- Queens, NY64 项研究
- Durham, NC64 项研究
- Chicago, IL59 项研究
- Philadelphia, PA56 项研究
- Dallas, TX55 项研究
Mountain View的其他研究
- 癌症（所有类型）40 项研究
- 转移性癌症25 项研究
- 非小细胞肺癌21 项研究
- 急性髓系白血病19 项研究
- 卵巢癌19 项研究
- 自闭症谱系障碍17 项研究
- 肺癌17 项研究
- 前列腺癌15 项研究
- 心力衰竭15 项研究
- 自闭症13 项研究
- 急性淋巴细胞白血病13 项研究
- 结直肠癌13 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。